Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience

Blood (2013) 122 (21): 3911.

https://doi.org/10.1182/blood.V122.21.3911.3911

Published: 2013

Journal Articles

Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Carlos Guillermo Romo, MD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Sherry Pierce, Mary Joy Liboon, Evguenia Gachimova, Tapan M. Kadia, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 4019.

https://doi.org/10.1182/blood.V122.21.4019.4019

Published: 2013

Journal Articles

Pancreatitis In Patients Treated With Brentuximab Vedotin: A Previously Unrecognized Serious Adverse Event

Mitul Gandhi, MD, Andrew M Evens, DO, MSc, Timothy S. Fenske, MD, Paul Hamlin, MD, Bertrand Coiffier, MD, PhD, Andreas Engert, MD, Alison J. Moskowitz, MD, Nilanjan Ghosh, MD, PhD, Adam M. Petrich, MD, Jon Lomasney, M.D., Amy Chadburn, M.D., Gary S. Wood, MD, Katrin Salva, M.D., Steven M Trifilio, BS Pharm, Dennis W. Raisch, PhD, MS, RPh, Dennis West, PhD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2013) 122 (21): 4380.

https://doi.org/10.1182/blood.V122.21.4380.4380

Published: 2013

Journal Articles

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Michael W Deininger, MD, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Neil Shah, MD, PhD, Dale Bixby, MD, PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Thomas O'Hare, PhD, Simin Hu, PhD, David J. Dorer, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Brian J. Druker, Moshe Talpaz, MD

Blood (2012) 120 (21): 3743.

https://doi.org/10.1182/blood.V120.21.3743.3743

Published: 2012

Journal Articles

Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

Andrew Spencer, MD, Sung-Soo Yoon, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Shannon Morris, MD, PhD, Deborah Smith, PharmD, Steven J. Freedman, MD, PhD, Richard Brigandi, MD, PhD, Allen Oliff, MD, Joanna B. Opalinska, MD, PhD, Christine Chen, MD

Blood (2011) 118 (21): 1856.

https://doi.org/10.1182/blood.V118.21.1856.1856

Published: 2011

Journal Articles

Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2 V617F Allele Burden

Animesh Pardanani, MBBS, PhD, Jason R Gotlib, MD, MS, Catriona Jamieson, MD, PhD, Jorge E. Cortes, MD, Moshe Talpaz, MD, Richard M Stone, M.D., Michael H Silverman, MD, FACP, Jolene Shorr, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD

Blood (2010) 116 (21): 459.

https://doi.org/10.1182/blood.V116.21.459.459

Published: 2010

Journal Articles

Comparative Cost for Required Monitoring to Detect Adverse Events or Laboratory Abnormalities: Dasatinib Versus Nilotinib.

W. Robert Simons, Ross Maclean, Jessica Cairns

Blood (2009) 114 (22): 4524.

https://doi.org/10.1182/blood.V114.22.4524.4524

Published: 2009

Journal Articles

Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance.

Hagop M. Kantarjian, MD, Andreas Hochhaus, MD, Jorge Cortes, MD, Giovanni Martinelli, MD, Kapil N. Bhalla, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Gert Ossenkoppele, MD, PhD, Norbert Gattermann, MD, PhD, Ariful Haque, Neil Gallagher, Michele Baccarani, MD, Philipp le Coutre, MD

Blood (2007) 110 (11): 735.

https://doi.org/10.1182/blood.V110.11.735.735

Published: 2007

NARROW

Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience

Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution

Pancreatitis In Patients Treated With Brentuximab Vedotin: A Previously Unrecognized Serious Adverse Event

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2 V617F Allele Burden

Comparative Cost for Required Monitoring to Detect Adverse Events or Laboratory Abnormalities: Dasatinib Versus Nilotinib.

Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only